Mirum Pharmaceuticals, Inc. MIRM Convertible Debt (Non-Current)
Convertible Debt (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s convertible debt (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s convertible debt (non-current)?
- Mirum Pharmaceuticals, Inc. (MIRM) reported convertible debt (non-current) of $310.25M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s convertible debt (non-current) changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s convertible debt (non-current) increased by 0.6% year-over-year, from $308.51M to $310.25M.
- What does convertible debt (non-current) mean?
- This represents the portion of long-term debt obligations that can be converted into equity shares of the company, with a maturity date exceeding one year. It reflects the company's reliance on hybrid financing instruments that provide capital while potentially diluting existing shareholders upon conversion. Investors analyze this to evaluate the company's long-term leverage, potential future equity dilution, and the impact of debt servicing on long-term capital structure.